Trials / Active Not Recruiting
Active Not RecruitingNCT04702880
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed participants with extensive-stage small cell lung cancer (ES-SCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BMS-986012 | Specified dose on specified days |
| DRUG | Carboplatin | Specified dose on specified days |
| DRUG | Etoposide | Specified dose on specified days |
| BIOLOGICAL | Nivolumab | Specified dose on specified days |
Timeline
- Start date
- 2021-03-17
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2021-01-11
- Last updated
- 2025-10-08
Locations
39 sites across 11 countries: United States, Australia, Belgium, Canada, Greece, Italy, Japan, Netherlands, Poland, Romania, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04702880. Inclusion in this directory is not an endorsement.